TW200920405A - PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis - Google Patents

PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis Download PDF

Info

Publication number
TW200920405A
TW200920405A TW097131697A TW97131697A TW200920405A TW 200920405 A TW200920405 A TW 200920405A TW 097131697 A TW097131697 A TW 097131697A TW 97131697 A TW97131697 A TW 97131697A TW 200920405 A TW200920405 A TW 200920405A
Authority
TW
Taiwan
Prior art keywords
double
prostate cancer
pkib
naaladl2
antibody
Prior art date
Application number
TW097131697A
Other languages
English (en)
Chinese (zh)
Inventor
Yusuke Nakamura
Hidewaki Nakagawa
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of TW200920405A publication Critical patent/TW200920405A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW097131697A 2007-08-24 2008-08-20 PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis TW200920405A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95785307P 2007-08-24 2007-08-24
US3603008P 2008-03-12 2008-03-12

Publications (1)

Publication Number Publication Date
TW200920405A true TW200920405A (en) 2009-05-16

Family

ID=40387239

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097131697A TW200920405A (en) 2007-08-24 2008-08-20 PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis

Country Status (10)

Country Link
US (1) US20120022128A1 (enExample)
EP (1) EP2195425A4 (enExample)
JP (1) JP2010536365A (enExample)
KR (1) KR20100075452A (enExample)
CN (1) CN101855346A (enExample)
BR (1) BRPI0815757A2 (enExample)
CA (1) CA2697512A1 (enExample)
RU (1) RU2010111116A (enExample)
TW (1) TW200920405A (enExample)
WO (1) WO2009028521A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945848B2 (en) * 2009-07-31 2015-02-03 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
KR101164645B1 (ko) * 2011-10-07 2012-07-20 대한민국 Gcpⅱ 돌연변이를 함유하는 알츠하이머 예방 및 치료용 약학적 조성물
GB201303308D0 (en) * 2013-02-25 2013-04-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
GB201304612D0 (en) * 2013-03-14 2013-05-01 Cancer Rec Tech Ltd Diagnostic and prognostic biomarkers for prostate cancer and other disorders
AU2014375206B2 (en) * 2014-01-03 2021-09-30 Innosign B.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression.
KR101824303B1 (ko) 2015-08-06 2018-01-31 부경대학교 산학협력단 종이형 전립선암 진단센서, 이의 제조방법, 및 이를 이용한 전립선암 진단방법
CN114177296B (zh) * 2021-12-16 2023-05-26 上海交通大学医学院附属第九人民医院 Mpc的过表达或活性提高在制备预防和/或治疗前列腺癌的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005044976A2 (en) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005083118A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Pin-prc transition genes
EP2343384A3 (en) * 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
WO2006026051A2 (en) * 2004-08-03 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP2336780A1 (en) * 2005-07-27 2011-06-22 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers

Also Published As

Publication number Publication date
WO2009028521A1 (en) 2009-03-05
CA2697512A1 (en) 2009-03-05
CN101855346A (zh) 2010-10-06
BRPI0815757A2 (pt) 2015-02-18
KR20100075452A (ko) 2010-07-02
US20120022128A1 (en) 2012-01-26
RU2010111116A (ru) 2011-09-27
JP2010536365A (ja) 2010-12-02
EP2195425A4 (en) 2011-01-19
EP2195425A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
JP4594085B2 (ja) ヒト結腸癌に関連する遺伝子およびポリペプチド
TW200920406A (en) EBI3, DLX5, NPTX1 and CDKN3 for target genes of lung cancer therapy and diagnosis
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのprmt1
JP2006517783A (ja) ヒト骨髄性白血病に関連する遺伝子およびポリペプチド
TW200922626A (en) Cancer-related genes, CDCA5, EPHA7, STK31 and WDHD1
JP2006518186A (ja) 前立腺癌関連遺伝子およびポリペプチド
JP5640263B2 (ja) Depdc1ポリペプチドを使用した膀胱癌の治療または予防のための方法
KR101820572B1 (ko) 만성골수성백혈병에 관한 정보 제공 방법
JP2010536365A (ja) 前立腺癌の治療及び診断の標的遺伝子のための、pkib及びnaaladl2
EP2436694B1 (en) Novel gpcr protein and use of same
JP2012501163A (ja) がんの治療および診断用の標的遺伝子としてのc12orf48
JP2012501167A (ja) 膵臓癌関連遺伝子ttll4
JP5028601B2 (ja) 乳癌に関連する遺伝子およびポリペプチド
CN101273131A (zh) 胰腺癌相关基因cst6和gabrp
JP2012501161A (ja) 癌の治療および診断の標的遺伝子としてのsyngr4
CN101278060B (zh) 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
WO2010023837A1 (en) Breast cancer related gene rqcd1
KR20100128326A (ko) 암 치료 및 진단을 위한 표적 유전자인 c2orf18
JP2012501162A (ja) 癌の治療および診断のための標的遺伝子としてのoip5
KR20090060183A (ko) Flj25416 유전자의 신규한 용도
CN120193075A (zh) LINC01355、miR-27b-3p和POGZ在甲状腺癌诊断和治疗中的应用
WO2010023854A1 (en) Cancer related gene, lgn/gpsm2
KR101796091B1 (ko) 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물
JP2013502203A (ja) 肺癌および食道癌関連遺伝子adamts18
JP2008505601A (ja) 前立腺癌に関連した遺伝子及びポリペプチド